中国P站

ISSN: 2476-2024

Diagnostic Pathology: Open Access
Open Access

Our Group organises 3000+ Global Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
  • Research Article   
  • Diagnos Pathol Open Access,

Stigmasterol Inhibits the Progression of Hepatocellular Carcinoma by Modulating the TLR4/MyD88/NF-κB Signaling Pathway

Yanhua Ma* and Chun Yu
Department of Animal Science, Institute of Animal Science, Beijing, China
*Corresponding Author : Yanhua Ma, Department of Animal Science, Institute Of Animal Science, Beijing, China, Email: 804862356@

Received Date: Aug 31, 2024 / Published Date: Sep 08, 2025

Abstract

Purpose: This study employs molecular docking and in vitro experiments to investigate the regulatory mechanism of stigmasterol on the TLR4/MyD88/NF-κB signaling pathway in hepatocellular carcinoma.

Methods: Molecular docking with the AutoDock program investigated stigmasterol's binding affinity with TLR4, MyD88, and NF-κB. Its impact on proliferation and migration was assessed via CCK8, wound healing, and Transwell assays, while clonogenicity was determined through clonogenic formation experiments. Apoptosis and cell cycle were examined using flow cytometry. Western blot analysis evaluated TLR4, MyD88, and NF-κB protein expression post-stigmasterol treatment.

Results: Molecular docking revealed favorable binding conformations of stigmasterol with TLR4, MyD88, and NF-κB. stigmasterol exhibited inhibitory effects on proliferation, migration, invasion, and clonogenicity of hepatocellular carcinoma cells in vitro. Additionally, it promoted apoptosis, suppressed the cell cycle, and reduced the protein expression of the TLR4/MyD88/NF-κB signaling pathway.

Conclusion: Stigmasterol suppresses the activity of hepatocellular carcinoma cells by modulating the TLR4/ MyD88/NF-κB signaling pathway.

Keywords: Stigmasterol, TLR4, MyD88, NF-Κb, Hepatocellular carcinoma

Citation: Ma Y, Yu C (2025) Stigmasterol Inhibits the Progression of Hepatocellular Carcinoma by Modulating the TLR4/MyD88/NF-脦潞B Signaling Pathway. Diagnos Pathol Open 10: 259.

Copyright: 漏 2025 Ma Y. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited.

Select your language of interest to view the total content in your interested language

Post Your Comment Citation
Share This Article
Article Usage
  • Total views: 317
  • [From(publication date): 0-0 - May 24, 2026]
  • Breakdown by view type
  • HTML page views: 245
  • PDF downloads: 72
International Conferences 2026-27
 
Meet Inspiring Speakers and Experts at our 3000+ Global

Conferences by Country

Medical & Clinical Conferences

Conferences By Subject

Top Connection closed successfully.